Flu/ Influenza vaccines : Current And Novel Approach

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use. The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

  • Genetic and evolution of virus and host
  • Risk management and effectiveness of vaccines
  • Targeting strategies for influenza vaccines
  • Adjuvants and their improvement issues
  • Clinical trails of influenza based vaccines

Related Conference of Flu/ Influenza vaccines : Current And Novel Approach

May 11-12, 2017

4th International congress on Infectious Diseases

Barcelona, Spain
August 21-23, 2017

3rd Annual Congress on Infectious Diseases

San Francisco, California, USA
September 04-05, 2017

Global Experts Meeting on Sexually Transmitted Diseases

Macau, Hong Kong
September 7-9, 2017

6thEuro-Global Conference on Infectious Diseases

Paris, France
September 13-14, 2017

6th Annual Bacteriology and Parasitology Meeting

Singapore
Sep 25-26, 2017

2nd International Conference on Infection Control

Chicago, Illinois, USA
October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA

Flu/ Influenza vaccines : Current And Novel Approach Conference Speakers

Recommended Sessions

Related Journals

Are you interested in